Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nutanix (NTNX) to Post Q3 Earnings: What Lies in Store?

Nutanix's (NTNX) third-quarter fiscal 2020 results are likely to have benefited from demand for its hybrid cloud solutions.

NVDA : 341.01 (-2.21%)
PANW : 231.79 (+0.27%)
ADMS : 2.81 (-2.77%)
NTNX : 24.91 (+2.05%)
Intuit (INTU) to Report Q3 Earnings: What's in the Cards?

Intuit's (INTU) fiscal Q3 earnings are likely to have gained from buoyant demand for Quickbooks Online. However, an extension on tax filing deadline is likely to have weighed on the top line.

CSCO : 45.96 (+2.50%)
NVDA : 341.01 (-2.21%)
INTU : 281.21 (-0.35%)
ADMS : 2.81 (-2.77%)
Palo Alto (PANW) to Report Q3 Earnings: What Lies in Store?

Palo Alto's (PANW) third-quarter fiscal 2020 earnings are likely to have gained from the strong adoption of Prisma and Cortex platforms.

CSCO : 45.96 (+2.50%)
NVDA : 341.01 (-2.21%)
PANW : 231.79 (+0.27%)
ADMS : 2.81 (-2.77%)
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson's disease - expands coverage with reduction of 'OFF' time and increased 'good ON' time

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it...

ADMS : 2.81 (-2.77%)
NortonLifeLock (NLOK) to Post Q4 Earnings: What's in Store?

NortonLifeLock's (NLOK) Q4 results are likely to reflect growth in bookings. However, high tax payments are likely to have put cash flow under pressure.

CSCO : 45.96 (+2.50%)
NVDA : 341.01 (-2.21%)
ADMS : 2.81 (-2.77%)
NLOK : 19.86 (-0.05%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 66,000...

ADMS : 2.81 (-2.77%)
Adamas: 1Q Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Thursday reported a loss of $16.6 million in its first quarter.

ADMS : 2.81 (-2.77%)
Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss

Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.

INCY : 98.22 (-0.47%)
AMGN : 224.81 (+1.08%)
ADMS : 2.81 (-2.77%)
MNK : 3.03 (-9.55%)
EchoStar (SATS) to Report Q1 Earnings: What's in the Offing?

Impact of higher churn rate with decline in enterprise services are likely to get reflected on EchoStar's (SATS) first-quarter 2020 results.

HAIN : 30.80 (+3.37%)
SATS : 31.90 (+3.07%)
ADMS : 2.81 (-2.77%)
IPHI : 121.21 (+0.08%)
A10 Networks (ATEN) to Report Q1 Earnings: What's in Store?

A10 Networks' (ATEN) first-quarter 2020 performance is likely to have benefited from business optimization and a strong product line.

HAIN : 30.80 (+3.37%)
ADMS : 2.81 (-2.77%)
ATEN : 6.86 (+1.78%)
IPHI : 121.21 (+0.08%)
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMS : 2.81 (-2.77%)
All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy

Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADMS : 2.81 (-2.77%)
Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas' management...

ADMS : 2.81 (-2.77%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees the option to purchase an aggregate of 86,000...

ADMS : 2.81 (-2.77%)
Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals,...

ADMS : 2.81 (-2.77%)
Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals,...

ADMS : 2.81 (-2.77%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted six new employees the option to purchase an aggregate of 70,000 shares...

ADMS : 2.81 (-2.77%)
Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of 6.74% and 0.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMS : 2.81 (-2.77%)
Adamas: 4Q Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Tuesday reported a loss of $23.1 million in its fourth quarter.

ADMS : 2.81 (-2.77%)
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?

Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.

ADMS : 2.81 (-2.77%)
ADRO : 3.28 (+2.82%)
VCEL : 14.31 (+2.14%)
CRON : 6.72 (+0.90%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.56 , SEDG +0.70 , THC +0.17 , TER +2.74 , LITE -0.66
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar